PerformanceRiskValuationProfitabilityCashflowLiquidityESGRevenue & Geographic ExposureForecastFinancial GrowthIncome GrowthCashflow GrowthBalance Sheet Growth
1.90 - 2.15
0.48 - 2.54
9.88M / 3.06M (Avg.)
-0.59 | -3.40
These metrics indicate whether the stock trades cheaply or expensively relative to its fundamentals. Value investors use them to find mispricings—buying stocks that appear undervalued, with solid long-term prospects and limited downside risk.
614.31
P/E of 614.31 versus zero earnings in Drug Manufacturers - Specialty & Generic. Walter Schloss would verify earnings quality.
3914.73
P/S exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 13.16. Jim Chanos would check for potential multiple compression risks.
36.09
P/B exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.86. Jim Chanos would check for potential asset write-down risks.
-721.92
Negative FCF while Drug Manufacturers - Specialty & Generic median P/FCF is -15.43. Seth Klarman would investigate cash flow improvement potential.
-3634.97
Negative operating cash flow while Drug Manufacturers - Specialty & Generic median P/OCF is -2.10. Seth Klarman would investigate operational improvement potential.
36.09
Fair value ratio exceeding 1.5x Drug Manufacturers - Specialty & Generic median of 2.86. Jim Chanos would check for valuation bubble risks.
0.04%
Positive earnings while Drug Manufacturers - Specialty & Generic median shows losses. Peter Lynch would examine earnings quality advantage.
-0.14%
Negative FCF while Drug Manufacturers - Specialty & Generic median yield is -0.19%. Seth Klarman would investigate cash flow improvement potential.